Development of a 3D Tissue Culture–Based High-Content Screening Platform That Uses Phenotypic Profiling to Discriminate Selective Inhibitors of Receptor Tyrosine Kinases

Tijmen H. Booij1*, Maarten J. D. Klop2*, Kuan Yan2, Csaba Szántai-Kis3, Balint Szokol3, Laszlo Orfi3,4, Bob van de Water1, Gyorgy Keri3,5, and Leo S. Price1,2

Abstract
3D tissue cultures provide a more physiologically relevant context for the screening of compounds, compared with 2D cell cultures. Cells cultured in 3D hydrogels also show complex phenotypes, increasing the scope for phenotypic profiling. Here we describe a high-content screening platform that uses invasive human prostate cancer cells cultured in 3D in standard 384-well assay plates to study the activity of potential therapeutic small molecules and antibody biologics. Image analysis tools were developed to process 3D image data to measure over 800 phenotypic parameters. Multiparametric analysis was used to evaluate the effect of compounds on tissue morphology. We applied this screening platform to measure the activity and selectivity of inhibitors of the c-Met and epidermal growth factor (EGF) receptor (EGFR) tyrosine kinases in 3D cultured prostate carcinoma cells. c-Met and EGFR activity was quantified based on the phenotypic profiles induced by their respective ligands, hepatocyte growth factor and EGF. The screening method was applied to a novel collection of 80 putative inhibitors of c-Met and EGFR. Compounds were identified that induced phenotypic profiles indicative of selective inhibition of c-Met, EGFR, or bispecific inhibition of both targets. In conclusion, we describe a fully scalable high-content screening platform that uses phenotypic profiling to discriminate selective and nonselective (off-target) inhibitors in a physiologically relevant 3D cell culture setting.

Keywords
3D tissue culture, high-content screening, phenotypic profiling, c-Met, EGFR

Introduction
While offering many practical advantages for cell-based screening, cells grown on tissue culture plastic lack normal cell-cell and cell-matrix interactions, resulting in deregulated growth, dedifferentiation, disruption of other processes, and a poor simulation of the in vivo (patho)physiology. 3D cell culture methods have been developed that enable a more in vivo like tissue architecture and are therefore expected to represent a more physiologically relevant context for the evaluation of bioactive molecules. Although gaining in popularity for small-scale analyses, 3D cultures have yet to be widely adopted for screening. A number of factors account for this, although high-throughput 3D imaging and the analysis of large and complex image data sets can represent the most significant barrier to the implementation of high-content 3D culture-based screening. As a result, where 3D assays are used for screening,
the most common end-point measurements tend to be biochemical determinations of cell viability, with the loss of potentially valuable phenotypic information.

Cells cultured in extracellular matrix (ECM)–containing hydrogels can generate complex multicellular tissues, supporting a higher level of tissue organization, such as formation of ductal structures by epithelial cells and complex networks of invasive tumor cells.\(^6\)–\(^10\) These features may be relevant to the pathology of the disease being studied and offer a context for screening for therapeutic molecules. Complex phenotypes can also be exploited for compound profiling, allowing compounds that affect different targets and therefore induce different phenotypes to be discriminated, potentially providing additional information on the biological effects of compounds that cannot be obtained from single end-point measurements.

In many cultured cells, activation of receptor tyrosine kinases results in increased proliferation and motility.\(^11\) Cell motility has previously been used as a readout for high-throughput small-molecule and small interfering RNA (siRNA) screens for inhibitors of c-Met signaling.\(^12\)–\(^14\) In 3D culture, activation of c-Met can result in invasion of tumor cells into the surrounding microenvironment,\(^15\) a process that closely resembles the in vivo pathophysiology. Similarly, activation of the epidermal growth factor (EGF) receptor is known to induce epithelial- to mesenchymal transition (EMT) and invasion in various cancer types.\(^16\),\(^17\) As expected, selective inhibition of the receptor tyrosine kinases inhibits the ligand-induced effects. However, compounds that inhibit multiple targets or are toxic may also inhibit ligand-induced effects. Here, we describe a 384-well screening assay that uses automated high-content analysis and profiling of 3D cultures of invasive prostate cancer tumor cells to identify selective inhibitors of the c-Met and EGF receptor (EGFR) tyrosine kinases.

**Materials and Methods**

**Cell Lines**

The human prostate adenocarcinoma cell line PC-3 was cultured in Dulbecco’s modified Eagle’s medium (DMEM)–F12 (Ham’s) growth medium (Gibco Fisher Scientific, Landsmeer, Netherlands), supplemented with 10% fetal bovine serum (FBS) (Gibco Fisher Scientific), 1 mM sodium pyruvate (Gibco Fisher Scientific), 1.5 g/L NaHCO\(_3\) (Merck, Schiphol-Rijk, Netherlands), 0.1 mM nonessential amino acids (Gibco Fisher Scientific), and 50 µg/mL gentamycin (Sigma Aldrich, Zwijndrecht, Netherlands). PC-3 cells were grown in 175-cm\(^2\) tissue culture flasks (Coming, Amsterdam, Netherlands) in culture medium as described above. Before reaching maximal density, cells were washed with 1× phosphate-buffered saline (PBS) (Sigma Aldrich) and trypsinized with 1× Trypsin (Gibco Fisher Scientific). Subsequently, medium was added and cells were pelleted by centrifugation and resuspended in FBS with 10% DMSO (Biosolve B.V., Valkenswaard, Netherlands) and stored in aliquots at −150 °C.

**3D Invasion Assay**

PC-3 cells were cultured in 384-well plates (Greiner Bio-One B.V., Alphen aan den Rijn, Netherlands) in 60% v/v growth factor–reduced Matrigel (>9 mg/mL) (Corning), which supported spheroid formation of the highly transformed PC-3 cells and invasion upon addition of motogenic cytokines. To generate gels, thawed cells were mixed with culture medium and growth factor–reduced Matrigel. Then, 14.5 µL of cell-gel mix was added to each well of a 384-well plate using a CyBi Selma 96/60 robotic liquid handler (Analytik Jena AG, Jena, Germany), at a final cell density of 2000 cells per well. After polymerization at 37 °C for 30 min, DMEM-F12 (Ham’s) growth medium containing growth factors (hepatocyte growth factor [HGF] or EGF) and compounds were added to the gel. The plate(s) were subsequently covered with a gas-permeable adhesive membrane (Thermo Scientific, Zwijndrecht, Netherlands). Compound exposures were performed for 96 h, after which gels were fixed with 3% formaldehyde (Sigma Aldrich), permeabilized with 0.2% Triton-X100 (Sigma Aldrich), and stained with 0.25 µM rhodamine-phalloidin (Sigma Aldrich) and 0.1% Hoechst 33258 (Sigma Aldrich) in PBS at 4 °C for 16 h. After staining, plates were washed in PBS and covered with a Greiner SilverSeal (Greiner Bio-One B.V., Alphen aan den Rijn, Netherlands).

**Compounds**

Anti c-Met and nontargeting control Fab antibodies were generously provided by Merus Biopharmaceuticals B.V. (Utrecht, Netherlands). c-Met inhibitor ArQ-197 (Tivantinib) was synthesized by Janssen Pharmaceutica NV (Beerse, Belgium), following the synthesis method published from ArQule, and subsequently sent to the authors as a gift from Souichi Ogata (Janssen Oncology R&D). Results were confirmed using a second source of ArQ-197 (SelleckChem/Bio-Connect B.V. Huisen, Huisen, Netherlands). EGFR inhibitor AG1478 was obtained from Santa Cruz (SC-200613; Bio-Connect B.V. Huisen). PHA-665752 was a gift from Pfizer, Inc. (La Jolla, CA, USA). A collection of 80 compounds selected to inhibit both EGFR and/or c-Met was generated by Vichem Chemie (Budapest, Hungary) (Suppl. Table S1).

**Imaging**

A BD Pathway 855 automated inverted fluorescence microscope (BD Biosciences, Breda, Netherlands) was used for automated imaging of 384-well plates (wide-field epifluorescence). This microscope was used to image both Hoechst 33258 and rhodamine-phalloidin staining, using a 4×
After 24 h, growth medium was replaced with starvation medium (without serum and antibiotics) containing test compounds. After 24 h of compound exposure, growth factors (20 ng/mL HGF/EGF) were added for 10 min. Protein was isolated using RIPA lysis buffer (1% w/v deoxycholate, 50 mM Tris [pH 7.5], 0.15 M NaCl, 0.1% sodium dodecyl sulfate [SDS], 1% NP-40, 2 mM EDTA, 1% protease inhibitor cocktail [Sigma Aldrich]) and quantified using the standard bicinchoninic acid (BCA) method according to the manufacturer’s instructions (Thermo Scientific). Western blot analysis was performed according to a standard protocol using phospho-c-Met (Tyr1234/1235) antibody (3077P; Cell Signaling) diluted 1:1000 in 5% BSA in TBS-T or phospho-EGFR (Tyr1173) (4407; Cell Signaling Technology B.V., Leiden, Netherlands) 1:1000 in 5% BSA in Tris-Buffered Saline with 0.05% Tween-20 (TBS-T). Phospho-c-Met and phospho-EGFR antibodies were detected using horseradish peroxidase (HRP)-conjugated anti-rabbit IgG secondary antibody (111-035-003; JacksonImmunoResearch, Suffolk, UK) and ECL Plus reagent (RPN2132; GE Healthcare Life Sciences, Eindhoven, Netherlands). Detection of antibody was performed using a LAS4000 scanner (GE Healthcare Life Sciences). Tubulin loading control was detected using an anti-Tubulin antibody (T-9026; Sigma-Aldrich) diluted 1:1000 in 5% BSA in TBS-T and an anti-mouse Alexa 647–linked IgG (115-605-006; JacksonImmunoResearch). The Alexa 647 signal was detected directly using the LAS4000.

**In Vitro Kinase Activity Measurement**

EGFR enzyme activity was assayed in 384 microtiter plates (Corning 3676) at three compound concentrations, in a total volume of 10 µL by the Transcreener ADP2 FP method (BellBrook Labs, Madison, WI). Assay buffer contained 20 mM HEPES (pH 7.5), 1 mM dithiothreitol (DTT), 10 mM MgCl₂, 2 mM MnCl₂, and 0.01% v/v NP40. The final EGFR concentration was 7 nM. Poly Glu-Tyr (4:1)/poly Glu-Tyr (4:1) was used as substrate at a final concentration of 0.01 mg/mL. The final adenosine triphosphate (ATP) concentration was at 7.52 µM. The enzyme reaction was incubated for 60 min and stopped by addition of 10 µL adenosine diphosphate (ADP) detection mixture (1×). Measurements were performed on a Tecan (Männedorf, Switzerland). Infinite M1000Pro reader. c-Met enzyme activity was assayed in 384 microtiter plates (Corning 3676) at three compound concentrations, in a total volume of 10 µL by the Transcreener ADP2 FP method (BellBrook Labs). Assay buffer contained 20 mM HEPES (pH 7.5), 1 mM DTT, 3 mM MgCl₂, 3 mM MnCl₂, and 0.01% v/v Tween-20. The final c-Met concentration was 8 nM. Poly Ala-Glu-Lys-Tyr (6:2:5:1) was used as substrate at a final concentration of 0.25 mg/mL. The final ATP concentration was at 9.6 µM. The enzyme reaction was incubated for 60 min and stopped by addition of 10 µL ATP detection mixture (1×). Measurements were performed using a Tecan Infinite M1000Pro reader.

**Western Blot Detection of Receptor Activation**

Phosphorylation status of c-Met and EGFR in response to 20 ng/mL HGF or 20 ng/mL EGF was evaluated by Western blot. Briefly, 10⁵ PC-3 cells were grown per well in 12-well plates. After 24 h, growth medium was replaced with starvation medium (without serum and antibiotics) containing test compounds. After 24 h of compound exposure, growth factors (20 ng/mL HGF/EGF) were added for 10 min. Protein was isolated using RIPA lysis buffer (1% w/w deoxycholate, 50 mM Tris [pH 7.5], 0.15 M NaCl, 0.1% sodium dodecyl sulfate [SDS], 1% NP-40, 2 mM EDTA, 1% protease inhibitor cocktail [Sigma Aldrich]) and quantified using the standard bicinchoninic acid (BCA) method according to the manufacturer’s instructions (Thermo Scientific). Western blot analysis was performed according to a standard protocol using phospho-c-Met (Tyr1234/1235) antibody (3077P; Cell Signaling) diluted 1:1000 in 5% BSA in TBS-T or phospho-EGFR (Tyr1173) (4407; Cell Signaling Technology B.V., Leiden, Netherlands) 1:1000 in 5% BSA in Tris-Buffered Saline with 0.05% Tween-20 (TBS-T). Phospho-c-Met and phospho-EGFR antibodies were detected using horseradish peroxidase (HRP)-conjugated anti-rabbit IgG secondary antibody (111-035-003; JacksonImmunoResearch, Suffolk, UK) and ECL Plus reagent (RPN2132; GE Healthcare Life Sciences, Eindhoven, Netherlands). Detection of antibody was performed using a LAS4000 scanner (GE Healthcare Life Sciences). Tubulin loading control was detected using an anti-Tubulin antibody (T-9026; Sigma-Aldrich) diluted 1:1000 in 5% BSA in TBS-T and an anti-mouse Alexa 647–linked IgG (115-605-006; JacksonImmunoResearch). The Alexa 647 signal was detected directly using the LAS4000.
Results

Quantification of Complex Phenotypic Changes of Prostate Cancer Cells Cultured in 3D in 384-Well Microplates

We developed a 3D cell culture screening method for tumor cell invasion driven by c-Met and EGFR. PC-3 cells were cultured in ECM protein-rich hydrogels in 384-well plates in the presence or absence of c-Met/EGFR agonists and antagonists. After fixation and staining with rhodamine-phalloidin to reveal the structure of prostate cancer tumoroids and Hoechst 33258 to label nuclei, gels were imaged in two fluorescence channels using a BD Pathway 855 (BD Biosciences), collecting paired stacks of xy images throughout the z-plane for each well. In-focus information from each image was extracted and a single xy image projection was generated (Suppl. Fig. S1).

In the absence of added c-Met or EGFR agonists, PC-3 cells developed into spheroids over a period of 4 days (Fig. 1A, upper panel). Treatment with the c-Met ligand (HGF) or the EGFR ligand (EGF) induced a highly invasive phenotype (Fig. 1A, middle and lower panels). To quantify these phenotypic changes in detail, Ominer and KNIME software were used to identify and quantify different morphological features from the 2D projections of the cytoskeleton and nuclei-derived image stacks. To do this, a collection of different image analysis algorithms was applied to derive measurements of the shape and fluorescence intensity of individual tumoroids, wavelets, and Hu and Zernike moments as previously described.22 Supervised PCA was used to reduce measurements from approximately 800 phenotypic parameters to principal components (PCs). EGF-treated and untreated PC-3 cells were used to train a profile to represent active and inactive EGFR inhibitors, respectively, which was subsequently scaled to percent stimulation. Similarly, a separate supervised analysis was performed that was trained with HGF-treated and untreated cells to separate phenotypes representing active c-Met from unstimulated control phenotypes. The primary principal component (PC0) was plotted for both EGF- and HGF-induced phenotypic changes to visualize the responses (Fig. 1B). Both HGF- and EGF-induced phenotypes of PC-3-derived tumoroids could be clearly discriminated from untreated tissues. Many of the phenotypic features separating HGF- and EGF-induced changes in phenotype from unstimulated controls describe shape, circularity, and intensity. The distance in phenotypic space along PC0 to the unstimulated controls was presented graphically as a function of EGF or HGF concentration (Fig. 1C).

Phenotypic Profiling Can Be Used to Quantify c-Met Activation and Inactivation

To test whether HGF-induced phenotypes could report c-Met activation, HGF was added in the presence of the c-Met function blocking Fab antibody, Genentech 5D5 Fab (Genentech, South San Francisco, CA). 5D5 antibody effectively inhibited the HGF-induced response (PC0, Fig. 2A), resulting in phenotypes that projected in a similar location to unstimulated controls in phenotypic space (represented by three principal components), with an inhibition that was dose dependent (Fig. 2A,B). The c-Met inhibitory antibody had no quantifiable effect on the PC-3 phenotype in the absence of HGF (Fig. 2A). In contrast, treatment of PC-3 cells with a c-Met activating antibody, the bivalent IgG form of 5D5, which crosslinks c-Met, induced a phenotype that was indistinguishable from that induced by HGF. Together these results confirm the c-Met dependency of the HGF-induced phenotype and demonstrate that principal components can be used to quantify HGF-induced phenotypic changes correlating with c-Met activation and inhibition.

Using Phenotype to Discriminate Compounds Based on Target Selectivity

To determine whether the phenotypic assay can discriminate between selective c-Met and EGFR inhibitors, PC-3 cells were cultured in the presence of either HGF or EGF, together with established small-molecule and antibody inhibitors of their cognate receptors. As expected, the small-molecule c-Met inhibitor PHA-66575223,24 selectively inhibited the phenotype induced by HGF. In contrast, the EGFR inhibitor AG147825 had no significant effect on the HGF-induced phenotype up to a concentration of 1 µM (Fig. 3A,C, right panel). Conversely, AG1478 but not PHA-665752 inhibited the EGF-induced phenotype (Fig. 3A,C, left panel). These findings suggest that residual c-Met and EGFR activity does not contribute to the 3D phenotype under the conditions used and that c-Met does not require EGFR for the ligand-induced response and vice versa. Interestingly, ArQ-197, which is reported to be a selective inhibitor of c-Met,22,26 inhibited both the HGF- and EGF-induced responses with a similar IC50, suggesting a more complex mechanism of action. At higher concentrations (>1 µM), this compound introduced a novel phenotype, shown by a shift away from the controls in a representation of phenotypic space (Fig. 3B).

To confirm that the interpretations based on phenotypic changes correlated with inhibition of receptor kinase activity, we performed Western blot analysis for phosphorylated c-Met (Y1234/-5) and phosphorylated EGFR (Y1173) (Fig. 3D). Results showed that PHA-665752 and the Genentech 5D5 Fab potently inhibited phosphorylation of c-Met but not EGFR phosphorylation. Conversely, AG1478 and cetuximab treatment inhibited phosphorylation of EGFR but not of c-Met. ArQ-197 did not show detectable inhibition of EGFR (Y1173) or c-Met (Y1234/-5) phosphorylation under these conditions (Fig. 3D). Therefore, inhibition
of phenotypes in 3D culture by c-Met and EGFR inhibitors correlates with inhibition of the respective kinases.

Taken together, these results show that measurement of ligand-induced phenotypic changes can be used to discriminate and measure inhibition of c-Met and EGFR.

**Using Phenotypic Profiles to Identify Novel Selective c-Met and EGFR Inhibitors**

Using data obtained from c-Met and EGFR in vitro kinase assays, a collection of 80 putative single- and dual-specificity EGFR and c-Met inhibitors was compiled (Suppl. Table S1), which included several well-characterized reference compounds. These were screened in 3D-cultured PC-3 cells together with several published reference inhibitors of c-Met and EGFR. All compounds were screened in 384-well plates at three concentrations (10 µM, 3.16 µM, and 1 µM) in triplicate plates in both EGF- and HGF-stimulated conditions. Multiparametric analysis was performed as before, followed by Z score normalization of each parameter to the plate median. Supervised PCA was used to condense phenotypic measurements to one phenotypic descriptor (PC0), which was scaled between 0% (unstimulated) and 100% (stimulated). Individual data points shown, as well as mean and standard deviations. (C) EGF and HGF cause a dose-dependent change in phenotype. Phenotypic change is derived from PC0 and scaled to percent response, as shown in B. Results are shown as means with standard deviation.

---

**Figure 1.** Receptor activation induces a quantifiable change in phenotype. (A) Typical images of unstimulated, hepatocyte growth factor (HGF)–stimulated, and epidermal growth factor (EGF)–stimulated PC-3 cells taken using a Nikon Ti Eclipse confocal microscope (Nikon, Tokyo, Japan). Receptor activation induced a change in phenotype characterized by invasion into the surrounding matrix. F-actin stained red; nuclei stained blue. (B) Phenotypic shift induced by HGF and EGF visualized using supervised (unstimulated-stimulated) principal components analysis (PCA). PC0 was scaled between 0% (unstimulated) and 100% (stimulated). Individual data points shown, as well as mean and standard deviations. (C) EGF and HGF cause a dose-dependent change in phenotype. Phenotypic change is derived from PC0 and scaled to percent response, as shown in B. Results are shown as means with standard deviation.
PC0 value, from the growth factor–treated to growth factor–untreated controls. Compounds that induced such a shift in the c-Met PC0 included various established c-Met reference inhibitors that were included in the screen, including the Genentech 5D5 Fab antibody, foretinib, and lower doses of PHA-665752. This confirmed that the phenotypic training using HGF-treated and untreated samples discriminated c-Met active and inactive conditions and was able to select compounds that induced a c-Met inhibitory phenotypic profile. Selective inhibition of the EGFR could be characterized by a horizontal shift to the left, from a profile associated with an EGF-stimulated phenotype to one associated with an unstimulated phenotype. This region contained several EGFR reference inhibitors, including erlotinib, gefitinib, and AG1478 (at 1 and 3.16 µM), which were included in the screen alongside test compounds. Compounds that clustered together with the unstimulated controls (Fig. 4A, bottom left quadrant) were predicted to have a dual-inhibitory activity for both c-Met and EGFR. The compounds clustering in this area included afatinib and also a number of previously untested compounds of the Vichem library. The class to which each compound was attributed using this approach is shown in Table 1 and Supplemental Table S2. By using another form of supervised clustering, linear discriminant analysis (LDA), we could separate the highly similar EGF- and HGF-induced phenotypes into a multidimensional plot (Suppl. Fig. S3). However, this approach did not improve classification of reference c-Met and EGFR inhibitor compounds.

Representative images of 3D-cultured PC-3 cells treated with EGFR and c-Met inhibitors are presented in Figure 4B and show a consistency between the automated classification of compounds to a specific inhibitory class and the phenotype that is induced in the presence of a specific growth factor. We compared the phenotypic classification of compounds with measurements of EGFR or c-Met enzyme inhibitory activity (Table 2 and Suppl. Table S3). Phenotypic classification was found to frequently overlap with biochemical measurements. Inhibition of c-Met activity in enzymatic and phenotypic assays was closely correlated, with all compounds showing greater than 40% inhibition in an enzymatic assay being inhibitory in the phenotypic assay at the equivalent concentration. However, approximately half of the compounds that were active in EGFR enzymatic assays were inactive in the cell-based phenotypic assays. Furthermore, several of the compounds that were inhibitory at the lowest doses in the EGFR enzymatic assay only showed activity in the corresponding phenotypic assay at higher concentrations (e.g., VCC833029:24, VCC740005:11, and VCC407451:10), indicating lower sensitivity of the phenotypic assay compared to the enzymatic assay. Not all compounds that induced enzymatic inhibition of EGFR and/or c-Met could be identified as inhibitors from our screening results, suggesting that enzymatic inhibition does not directly translate to a phenotypic change under all conditions.

We then compared ranking of compounds based on phenotypic profiling with ranking based on cell count. Cell count was determined by the number of nuclei counted per well (one of the many features scored by the multiparametric analysis) and is a feature that correlates closely with biochemical measurements of cell proliferation (not shown). Using a ranking based on cell proliferation, inhibitors that were shown to potently inhibit the c-Met phenotype, including Genentech 5D5 Fab, did not score in the top 10% inhibitors of proliferation (Fig. 4C and Suppl. Fig. S4). Consistent
with the profiling results in Figure 4A, when compounds were ranked based on the difference in their phenotypic profiles to unstimulated controls (measured along PC0), a strong enrichment of c-Met and EGFR inhibitors was observed in the top 10% of ranked compounds in the presence of HGF and EGF, respectively (Suppl. Fig. S4). The most potent inhibitors of proliferation were found to perform poorly when ranked based on their phenotypic profiles (Fig. 4C). An analysis of the images from 3D cultures treated with these compounds showed that spheroid formation was disrupted, consistent with cytotoxicity of these compounds.

**Discussion**

Because tumor cells exist in a 3D ECM-rich environment, 3D matrix-embedded cell cultures provide a more physiologically relevant context in which to perform compound...
Figure 4. Identification of selective c-Met/EGFR inhibitors in a Vichem epidermal growth factor (EGF) receptor (EGFR)/c-Met inhibiting compound library. (A) Compound screen of 80 Vichem compounds tested at 10, 3.16, and 1 µM. Compounds were divided over triplicate plates and coexposed with either hepatocyte growth factor (HGF) (20 ng/mL) or EGF (20 ng/mL). Principal components analysis (PCA) was trained on unstimulated and stimulated controls separately for plates exposed to HGF or EGF, respectively, to obtain a principal component that could separate c-Met and EGFR responses. Data points represent mean determinations from three wells. Controls are color-coded as indicated in the legend. For stimulated (top middle) and unstimulated controls (bottom left), a 2D-density estimation (contour lines) is shown. (B) Representative 2D projected images derived from the F-actin staining after 96 h of compound treatment. Except for AG1478, which was 3.16 µM, shown treatment concentrations were 10 µM. Pictures were obtained using a BD Pathway 855 microscope (images trimmed to 300 × 300 pixels for presentation purposes). (C) Cell count (viability) is a poor criterion for selecting c-Met and EGFR inhibitors. Number of nuclei per well was percent normalized to stimulated control (100%) and lowest detected cell count and 0%, top panel. The top ranking 10% of compounds affecting cell count are color-coded in red. Middle and lower panels show the same compounds ranked on efficacy on c-Met and EGFR profiles (distance to unstimulated control). Mean values shown; each chart contains compounds at three different concentrations.
The increased complexity of 3D cultures also offers increased potential for phenotypic profiling. We developed a fully scalable 3D tissue culture–based high-content screening platform that uses phenotypic profiling of cultured tumoroids derived from a prostate cancer cell line. This screening platform was used to identify several selective inhibitors for c-Met and EGFR, which represent important targets in many cancers and are known to stimulate survival and invasive growth of tumors. We show that activation of c-Met with its ligand, HGF, induced a dose-dependent reorganization of PC-3 spheroids characterized by invasion of cells into the surrounding matrix. A similar change in phenotype was induced by the addition of EGF to the PC-3 cells. These phenotypic changes were not observed in 2D monolayers. Ultra-high-content multiparametric analysis allowed a clear discrimination of the phenotypes associated with active and inactive c-Met and EGFR, which could be quantified using a single PCA measurement. This approach allowed us to discriminate inhibitors of c-Met and EGFR and also putative biselective inhibitors of these receptor tyrosine kinases. The method also enabled nonselective compounds to be discriminated since they induced phenotypes that failed to match those induced by selective inhibition of c-Met or EGFR. The screening results were cross-validated with an in vitro measurement of enzyme activity and were found to largely correlate. Some compounds that inhibited EGFR or c-Met in the biochemical measurement were not identified by our phenotypic screen as inhibitors for these pathways, indicating that inhibition of purified enzyme does not always correlate with inhibition of the target enzyme in cells. These differences may be explained by poor compound stability over multiple days in aqueous solution (medium) or poor membrane permeability, resulting in lower cytoplasmic concentrations. It is also possible that these compounds induce mild phenotypic changes that are below the threshold of the phenotypic assay. A number of compounds were found to induce phenotypic changes in the EGFR and/or c-Met profiles, even though these failed to induce inhibition of either EGFR or c-Met activity. A possible explanation for this finding is that these molecules induced off-target phenotypic effects that could not be discriminated from inhibition of c-Met and EGFR.

Improvements in 3D cell culture reagents, methods, and automated microscopes that can capture 3D image data are making screening in 3D more accessible, including more complex models such as co-cultures. Here we describe how high-content analysis can maximize the information that can be extracted from the more complex phenotypes obtained in 3D cell culture. These include disease-relevant

### Table 1. Hit Selection Phenotypic Screen.

| Vichem Compound ID | 1 µM  | 3.16 µM  | 10 µM  |
|--------------------|-------|----------|--------|
| VCC030450:22      | EGFR  | EGFR     | EGFR   |
| VCC048363:02      | EGFR  | EGFR     | EGFR/c-Met |
| VCC055393:01      | EGFR/c-Met | EGFR/c-Met | EGFR/c-Met |
| VCC109756:01      | c-Met | c-Met    | c-Met  |
| VCC1155409:01     | None  | None     | EGFR/c-Met |
| VCC228833:01      | None  | None     | Top 10% cell count |
| VCC285946:01      | None  | c-Met    | c-Met  |
| VCC376189:01      | c-Met | c-Met    | EGFR/c-Met |
| VCC378728:01      | None  | EGFR     | None   |
| VCC407451:10      | None  | EGFR     | EGFR   |
| VCC415997:02      | c-Met | c-Met    | c-Met  |
| VCC429285:02      | None  | None     | EGFR/c-Met |
| VCC444414:01      | c-Met | c-Met    | c-Met  |
| VCC450892:17      | c-Met | c-Met    | c-Met  |
| VCC497510:01      | c-Met | c-Met    | EGFR/c-Met |
| VCC502987:01      | None  | None     | EGFR/c-Met |
| VCC528301:01      | None  | None     | EGFR/c-Met |
| VCC665676:02      | None  | None     | None   |
| VCC716837:01      | None  | None     | Top 10% cell count |
| VCC740005:11      | None  | EGFR     | EGFR   |
| VCC744093:03      | None  | None     | None   |
| VCC833029:24      | None  | None     | EGFR   |
| VCC868449:01      | None  | None     | EGFR/c-Met |
| VCC960450:01      | c-Met | c-Met    | c-Met  |

EGFR, epidermal growth factor receptor.
Table 2. Enzyme Activity Measurement (Percent Inhibition).

| Inhibition (%) | EGFR 10 µM | EGFR 1 µM | EGFR 0.1 µM | c-Met 10 µM | c-Met 1 µM | c-Met 0.1 µM |
|----------------|------------|-----------|-------------|-------------|-------------|-------------|
| VCC030450:22   | 101        | 99        | 97          | 4           | 2           | 0           |
| VCC048363:02   | 101        | 100       | 97          | 1           | –1          | –2          |
| VCC055393:01   | 99         | 100       | 100         | 3           | 3           | –4          |
| VCC109756:01   | 43         | 7         | 2           | 93          | 61          | 7           |
| VCC155409:01   | 76         | 34        | 10          | 25          | 2           | –2          |
| VCC228833:01   | 16         | 1         | 0           | 4           | 0           | –2          |
| VCC285946:01   | 32         | 0         | 9           | 84          | 49          | 8           |
| VCC376189:01   | 12         | 2         | –2          | 83          | 56          | 9           |
| VCC378728:01   | 85         | 41        | 8           | 72          | 16          | 0           |
| VCC407451:10   | 93         | 92        | 73          | 7           | 0           | –4          |
| VCC415997:02   | –11        | –11       | –7          | 95          | 77          | 14          |
| VCC429285:02   | 3          | 2         | 0           | 6           | –2          | 2           |
| VCC444414:01   | 7          | –4        | –6          | 90          | 47          | 3           |
| VCC450892:17   | 32         | 10        | 5           | 85          | 39          | 4           |
| VCC497510:01   | 20         | 10        | 2           | 90          | 54          | 9           |
| VCC502987:01   | 19         | 9         | 1           | 4           | 1           | 0           |
| VCC528301:01   | 94         | 82        | 29          | 37          | 7           | 1           |
| VCC656576:02   | 2          | –7        | –13         | 0           | –4          | –4          |
| VCC716837:01   | 48         | 10        | 1           | 41          | 6           | 0           |
| VCC740005:11   | 105        | 102       | 93          | 11          | 1           | 3           |
| VCC744093:03   | 77         | 25        | 3           | 27          | –1          | –1          |
| VCC833029:24   | 97         | 90        | 37          | –3          | 0           | 0           |
| VCC868449:01   | 95         | 89        | 37          | 56          | 14          | 3           |
| VCC960450:01   | –11        | –7        | –10         | 87          | 50          | 11          |

Scale of red to green shading used to visualise % inhibition. Red, no inhibition of target; Yellow, mild target inhibition; Green, potent inhibition of target. EGFR, epidermal growth factor receptor.

features, such as tumor cell invasion, but also a multitude of other features that can be exploited for profiling purposes. Thus, in addition to screening for inhibition of a disease phenotype, target-based screening can be performed. Traditionally, receptor activation has been measured using biochemical methods. While sensitive, these methods do not discriminate nonselective inhibition of the target. An advantage of the multiparametric profiling approach described here is that in addition to detecting inhibition of the c-Met and EGFR, off-target effects can also be detected if the off-targets have an impact on tissue phenotype.

Our method was used to determine inhibitory activity of both small molecules and antibodies. We applied the method to both c-Met and EGFR, but in principle, it can be applied to any target if a cell line can be identified in which the activity of the target influences cell phenotype. Combining the advantages of physiological relevance and phenotypic complexity, phenotypic screening and profiling with 3D cell cultures has the potential to improve the quality of hits from screens and make previously challenging targets more accessible, potentially leading to a higher success rate of molecules in clinical trials.

Acknowledgments

We thank Souichi Ogata (Janssen Oncology R&D) for kindly providing ArQ-197 and Rob Roovers (Merus) for providing the Genentech 5Ds Fab and IgG. Furthermore, we thank Dr. Marc Bickle, Max Planck, Dresden, for introducing us to the KNIME software.

Declaration of Conflicting Interests

L. S. Price is a founder and major share holder of OcellO B.V. The other authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Funding
T. H. Booj is supported by the Dutch Technology Foundation STW (Project 11823), which is part of The Netherlands Organization for Scientific Research (NWO). The other authors received no financial support for the research, authorship, and/or publication of this article. The authors received no financial support for the research, authorship, and/or publication of this article.

References
1. Mishra, D. K.; Sakamoto, J. H.; Thrall, M. J.; et al. Human Lung Cancer Cells Grown in an Ex Vivo 3D Lung Model Produce Matrix Metalloproteinases Not Produced in 2D Culture. *PLoS One*. 2012, 7, e45308.
2. Bradbury, P.; Fabry, B.; O’Neil, G. M. Occupy Tissue: The Movement in Cancer Metastasis. *Cell Adh. Migr.* 2012, 6, 424–432.
3. Smalley, K. S.; Lioni, M.; Herlyn, M. Life Isn’t Flat: Taking Cancer Biology to the Next Dimension. In *In Vitro Cell Dev. Biol. Anim.* 2006, 42, 242–247.
4. Breslin, S.; O’Driscoll, L. Three-Dimensional Cell Culture: The Missing Link in Drug Discovery. *Drug Discov. Today*. 2013, 18, 240–249.
5. Li, L.; Zhou, Q.; Voss, T. C.; et al. High-Throughput Imaging: Focusing on in Drug Discovery in 3D. *Methods* 2016, 96, 97–102.
6. Taubenberger, A. V.; Bray, L. J.; Haller, B.; et al. 3D Extracellular Matrix Interactions Modulate Tumour Cell Growth, Invasion and Angiogenesis in Engineered Tumour Microenvironments. *J. Act. Bio.* 2016, 36, 73–85.
7. Debnath, J.; Brugge, J. S. Modelling Glandular Epithelial Cancers in Three-Dimensional Cultures. *Nat. Rev.* 2005, 5, 675–688.
8. Schmeichel, K. L.; Bissell, M. J. Modeling Tissue-Specific Signaling and Organ Function in Three Dimensions. *J. Cell Sci.* 2003, 116(Pt 12), 2377–2388.
9. O’Brien, L. E.; Zegers, M. M.; Mostov, K. E. Opinion: Building Epithelial Architecture: Insights from Three-Dimensional Culture Models. *Nat. Rev. Mol. Cell Biol.* 2002, 3, 531–537.
10. Härmi, V.; Knauttila, M.; Virtanen, J.; et al. Lysophosphatidic Acid and Sphinogosine-1-Phosphate Promote Morphogenesis and Block Invasion of Prostate Cancer Cells in Three-Dimensional Organotypic Models. *Oncogene* 2014, 31, 2075–2089.
11. Ren, Y.; Cao, B.; Law, S.; et al. Hepatocyte Growth Factor Promotes Cancer Cell Migration and Angiogenic Factors Expression: A Prognostic Marker of Human Esophageal Squamous Cell Carcinomas. *Clin. Cancer Res.* 2005, 11, 6190–6197.
12. Chan, G. K. Y.; Lutterbach, B. A.; Pan, B.-S.; et al. High-Throughput Analysis of HGF-Stimulated Cell Scattering. *J. Biomol. Screen.* 2008, 13, 847–854.
13. Radtke, S.; Milanovic, M.; Rossé, C.; et al. ERK2 but Not ERK1 Mediates HGF-Induced Motility in Non–Small Cell Lung Carcinoma Cell Lines. *J. Cell Sci.* 2013, 126, 2381–2391.
14. Zaritsky, A.; Natan, S.; Ben-Jacob, E.; et al. Emergence of HGF/SF Induced Coordinated Cellular Motility. *PLoS One* 2012, 7, e44671.
15. Comoglio, P. M.; Trusolino, L. Invasive Growth: From Development to Metastasis. *J. Clin. Invest.* 2002, 109, 857–862.
16. Hardy, K. M.; Booth, B. W.; Hendrix, M. J. C.; et al. ErbB/EGF Signaling and EMT in Mammary Development and Breast Cancer. *J. Mammary Gland. Biol. Neoplasia*. 2010, 25, 191–199.
17. Appert-Collin, A.; Hubert, P.; Crémel, G.; et al. Role of ErbB Receptors in Cancer Cell Migration and Invasion. *Front. Pharmacol.* 2015, 6, 1–10.
18. Zi, D.; Klop, M. J.; Rogkoti, M.; et al. Ultra High Content Analysis and Phenotype Profiling of 3D Cultured Micro-Tissues. *PLoS One* 2014, 9, e109688.
19. Venables, W. N.; Ripley, B. D. Modern Applied Statistics with S; Springer: New York, 2002; 4th ed.